HEALTH
Revision of Specifications and Rate for Inactivated Influenza Vaccine by ESIC
By TEAM CIRCULAR EXPRESS • 09 Nov 2026
👁 2 views
• ESIC has issued an amendment regarding the Inactivated Influenza Vaccine (Vaxiflu) supplied by M/s. Zydus Lifesciences Limited.
• The vaccine specification is revised from Tetralent to Trivalent.
• The rate is revised to Rs. 725.00 + GST per 0.5ml PFS.
• This arrangement remains effective until the validity of DGESIC RC-156 or the finalization of fresh Tender Enquiry No. TE-172, whichever is earlier.
• The vaccine specification is revised from Tetralent to Trivalent.
• The rate is revised to Rs. 725.00 + GST per 0.5ml PFS.
• This arrangement remains effective until the validity of DGESIC RC-156 or the finalization of fresh Tender Enquiry No. TE-172, whichever is earlier.
Organisation
Employees' State Insurance Corporation (ESIC)
Purpose of issue
Revision in specifications, brand name, and rate of approved item no. 2228
Name of Item
Inactivated Influenza Vaccine (Vaxiflu)
Revised Rate
Rs. 725.00 + GST per 0.5ml PFS
Tender Reference
DGESIC RC 156
Vendor Name
M/s. Zydus Lifesciences Limited
🔒 Document — view only
Regards, Circular Express
Similar Circulars
Provisional Superannuation List of Group A and B Officers at ESIC for 2027
#ESIC#General#Health
CME Update for October 2026 at ESIC Medical College
#ESIC#General#Health
Interview Rescheduling for ICMR Research Project at VMMC & Safdarjung Hospital
#Contract#Contractual#Health
Undertaking and Certificate for Land Suitability for ESIC Projects
#General#Health
Empanelment of Private Hospitals for Municipal Corporation of Delhi Employees and Pensioners
#Delhi#Empanelment#Haryana
Guidelines for Assessment of Land Suitability for ESIC Infrastructure Projects
#ESIC#General#Guidelines
You are viewing
Revision of Specifications and Rate for Inactivated Influenza Vaccine by ESIC
For Circular Express Members Only
Enter your registered 10-digit mobile number to view this circular.
Member Verified
LOGIN FOR PERMANENT ACCESSOne Time Access shows this circular only. Login keeps you signed in for all circulars.
HEALTH
Revision of Specifications and Rate for Inactivated Influenza Vaccine by ESIC
By TEAM CIRCULAR EXPRESS • 09 Nov 2026
👁 2 views
• ESIC has issued an amendment regarding the Inactivated Influenza Vaccine (Vaxiflu) supplied by M/s. Zydus Lifesciences Limited.
• The vaccine specification is revised from Tetralent to Trivalent.
• The rate is revised to Rs. 725.00 + GST per 0.5ml PFS.
• This arrangement remains effective until the validity of DGESIC RC-156 or the finalization of fresh Tender Enquiry No. TE-172, whichever is earlier.
• The vaccine specification is revised from Tetralent to Trivalent.
• The rate is revised to Rs. 725.00 + GST per 0.5ml PFS.
• This arrangement remains effective until the validity of DGESIC RC-156 or the finalization of fresh Tender Enquiry No. TE-172, whichever is earlier.
Organisation
Employees' State Insurance Corporation (ESIC)
Purpose of issue
Revision in specifications, brand name, and rate of approved item no. 2228
Name of Item
Inactivated Influenza Vaccine (Vaxiflu)
Revised Rate
Rs. 725.00 + GST per 0.5ml PFS
Tender Reference
DGESIC RC 156
Vendor Name
M/s. Zydus Lifesciences Limited
🔒 Document — view only
Regards, Circular Express
Similar Circulars
Provisional Superannuation List of Group A and B Officers at ESIC for 2027
#ESIC#General#Health
CME Update for October 2026 at ESIC Medical College
#ESIC#General#Health
Interview Rescheduling for ICMR Research Project at VMMC & Safdarjung Hospital
#Contract#Contractual#Health
Undertaking and Certificate for Land Suitability for ESIC Projects
#General#Health
Empanelment of Private Hospitals for Municipal Corporation of Delhi Employees and Pensioners
#Delhi#Empanelment#Haryana
Guidelines for Assessment of Land Suitability for ESIC Infrastructure Projects
#ESIC#General#Guidelines
